Inter- and intrasubject variations of ranitidine pharmacokinetics after oral administration to normal male subjects. 1989

C K Shim, and J S Hong
College of Pharmacy, Seoul National University, Korea.

Inter- and intrasubject variations of ranitidine pharmacokinetics were examined following oral administration of ranitidine tablets (150 mg as base) under controlled conditions at a timed interval of one week (periods I and II) to 12 healthy male subjects. Significant secondary peaks in the plasma concentration-time curves were observed in all subjects in both periods. The first peak occurred at 0.5 to 2.5 h and the second peak at 3 to 6 h after the dosing. There were great variations in the plasma concentration-time profiles among subjects; for example, the area under the plasma concentration-time curve from time 0 to 12 h (AUC0-12) varied from 1905 to 5672 micrograms.h/mL. But bioavailability parameters of period I, such as maximum concentration of the first and second plasma peak (Cmax 1 and Cmax 2, respectively), time to first peak (tmax 1), AUC0-12, and AUC from time zero to infinity (AUC0-infinity), were correlated significantly with those of period II. These results suggest that the intrasubject variation of ranitidine pharmacokinetics is usually small over at least one week under the controlled conditions of this study, in spite of its great intersubject variation.

UI MeSH Term Description Entries
D008297 Male Males
D011899 Ranitidine A non-imidazole blocker of those histamine receptors that mediate gastric secretion (H2 receptors). It is used to treat gastrointestinal ulcers. AH-19065,Biotidin,N (2-(((5-((Dimethylamino)methyl)-2-furanyl)methyl)thio)ethyl)-N'-methyl-2-nitro-1,1-ethenediamine,Ranisen,Ranitidin,Ranitidine Hydrochloride,Sostril,Zantac,Zantic,AH 19065,AH19065,Hydrochloride, Ranitidine
D002851 Chromatography, High Pressure Liquid Liquid chromatographic techniques which feature high inlet pressures, high sensitivity, and high speed. Chromatography, High Performance Liquid,Chromatography, High Speed Liquid,Chromatography, Liquid, High Pressure,HPLC,High Performance Liquid Chromatography,High-Performance Liquid Chromatography,UPLC,Ultra Performance Liquid Chromatography,Chromatography, High-Performance Liquid,High-Performance Liquid Chromatographies,Liquid Chromatography, High-Performance
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000284 Administration, Oral The giving of drugs, chemicals, or other substances by mouth. Drug Administration, Oral,Administration, Oral Drug,Oral Administration,Oral Drug Administration,Administrations, Oral,Administrations, Oral Drug,Drug Administrations, Oral,Oral Administrations,Oral Drug Administrations
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D001682 Biological Availability The extent to which the active ingredient of a drug dosage form becomes available at the site of drug action or in a biological medium believed to reflect accessibility to a site of action. Availability Equivalency,Bioavailability,Physiologic Availability,Availability, Biologic,Availability, Biological,Availability, Physiologic,Biologic Availability,Availabilities, Biologic,Availabilities, Biological,Availabilities, Physiologic,Availability Equivalencies,Bioavailabilities,Biologic Availabilities,Biological Availabilities,Equivalencies, Availability,Equivalency, Availability,Physiologic Availabilities

Related Publications

C K Shim, and J S Hong
May 1992, Biopharmaceutics & drug disposition,
C K Shim, and J S Hong
November 1998, Arzneimittel-Forschung,
C K Shim, and J S Hong
January 1981, European journal of clinical pharmacology,
C K Shim, and J S Hong
January 1989, Pharmaceutical research,
C K Shim, and J S Hong
December 1990, British journal of clinical pharmacology,
C K Shim, and J S Hong
April 1983, Clinical pharmacology and therapeutics,
Copied contents to your clipboard!